TORONTO – February 11, 2020 isoSolutions Marketing & Management Inc. (isoSolutions), an innovative one stop shop when it comes to nuclear medicine products has joined a growing list of organizations as members of the Canadian Nuclear Isotope Council (CNIC) an independent body made up of representatives from the Canadian health sector, nuclear industry and leading research groups, convened to promote Canada’s role in the production of the world’s supply of radioisotopes.

• 

Medical isotopes are very important, particularly for diagnostic purposes in oncology; cardiology and neurology. Canada has been a pioneer in the development of radioisotopes, saving millions of lives in more than 80 countries for over six decades. We have demonstrated world-class nuclear expertise and achievements, leading to significant advancements in medical imaging, cancer therapy, sterilization, food and water safety, and disease prevention.

“A secure supply of a diverse portfolio of isotopes is essential to maintaining and improving our standard of living. Isotopes are used every day to verify the safety of our roadways, discover and develop natural resources, test industrial products, and support research in mental health and aging,” said James Scongack- Chair of the CNIC. People suffering from these horrible illnesses are counting on Canada. Now more than ever it’s time for Canada to lead. When it comes to meeting some of the world’s greatest health challenges, all eyes are on Canada. We need to step up and provide the leadership in this area the world has always counted on Canada for.

“People and patients matter the most. Every organization should aim to leave people better off. In the health sector that starts with the patient but must also include our suppliers, customers, employees, partners — indeed, everyone whose life is touched by isotopes in some way,” said David Drummond, Managing Director of isoSolutions. “If Canada is to maintain its standing as a leading force in global science — and enjoy the associated economic and societal benefits — partnerships like this one with the CNIC will help us get there.”

A report released by the CNIC in September highlighted the need for strong Canadian leadership to ensure a domestic and international supply of medical isotopes. This presents a major challenge – and opportunity – for Canadian leadership in the training, research, development, deployment and export of medical isotopes for the global market. The report makes it clear that Canada must enable investment in its isotope infrastructure and ensure the building blocks are in place for this sector to remain a global leader. Such investments would exhibit a commitment to Canada’s role as a leader in nuclear medicine, and dramatically bolster the country’s capacity to innovate while delivering substantial economic and societal benefits to both Canadians and patients around the globe.

Added Scongack, “I believe the Canadian Nuclear Isotope Council (CNIC) has grown to over 55 respected members from across the Country in 2019 will play a role working alongside these organizations and both Provincial and Federal levels of Government and also expand the partners in this mission.”

This year the CNIC will continue to promote public awareness about the use and benefits of medical/industrial isotopes and radiation technologies, and work with government stakeholders to ensure that the public policy landscape promotes innovation and supports the increased proliferation of medical and industrial isotope uses.

About The Canadian Nuclear Isotope Council

The CNIC is a coalition of science, health care and nuclear sector organizations to ensure Canada remains a world leader in the production of life-saving isotopes by bringing awareness and supporting long-term policies at the domestic and international level that will save countless lives and support health-care innovation for decades to come. To learn more about the CNIC visit www.CanadianIsotopes.ca and follow us on, Facebook, Twitter, and LinkedIn.

For more information, please contact:
Andrew Thiele
Strategist, Government and Stakeholder Relations – Corporate Affairs
Canadian Nuclear Isotope Council
226.930.1869
canadianisotopes@gmail.com

About isoSolutions Marketing & Management Inc.

isoSolutions provides a one-stop shopping service as well as technical support worldwide for nuclear medicine applications including: Radiochemicals, Stable isotopes, Labeled compounds, Sealed sources, Synthesizers and Peptides. We provide a complete range of Radioisotopes, including a Ga-68 Generator, Lu-177, Y-90, a Re-188 Generator, I-131, I-125 and cyclotron products.

These products are complemented by an automated labeling module for development work or preprogrammed syntheses and a complete line of quality control instruments. We also offer consulting services for radiochemistry, grant applications and licensing (CMC sections, INDs, DMFs) in several regions of the globe. For more information, please contact:

Pat Acton
Sales Manager, Canada
pacton@isosolutions.com
+1(250) 889-5602
www.isoSolutions.com

Abstract :

Targeted radiotherapy is an evolving and promising modality of cancer treatment. The killing of cancer cells is achieved with the use of biological vectors and appropriate radionuclides. Among the many advantages of this approach are its selectiveness in delivering the radiation to the target, relatively less severe and infrequent side effects, and the possibility of assessing the uptake by the tumor prior to the therapy. Several different radiopharmaceuticals are currently being used by various administration routes and targeting mechanisms. This article aims to briefly review the current status of targeted radiotherapy as well as to outline the advantages and disadvantages of radionuclides used for this purpose.

Introduction:

The development and evolution of modern chemotherapy during the second half of the twentieth century has improved the clinical outcome of patients with various forms of cancer. Still, in the vast majority of malignancies, the efficacy of systemic chemotherapy is very limited, with 90% of all drug cures occurring in only 10% of cancer types. Unlike systemic chemotherapy, the goal of targeted radiotherapy is the selective delivery of radiation to cancer cells in a way that causes minimal toxicity to surrounding normal tissues. The basis for successful radionuclide therapy is selective concentration and prolonged retention of the radiopharmaceutical within the tumor. Tumor response depends on numerous factors, including cumulative radiation dose delivered, dose penetration, and tumor radiosensitivity. The radiation effect is maximally achieved when the radiation dose is entirely absorbed by the tumor. In practice however, this is almost never the case because of biologic turnover.

Radiopharmaceuticals and Targeting Mechanisms: The selection of the appropriate radionuclide depends on its nuclear decay properties, specifically, emission characteristics and physical half-life. The treatment of bulky tumors by radionuclides that emit high energy alpha or beta particles is the preferred approach (Tables 1 and 2); however, for the eradication of small clusters of cancer cells or small tumor deposits, radionuclides that emit Auger electrons are considered to be beneficial because of their high level of cytotoxicity and short-rangebiological effectiveness.

Conclusions:

In this article we have presented a brief review of commonly used targeted radionuclide therapeutic agents. We believe that changes in targeted radiotherapy will continue to improve alongside of progress in tumor biology research. Many institutions are formulating sophisticated radiopharmaceuticals including antibodies, fusion proteins, peptides and small organic molecules as well as sodium iodide gene transfer into tumor cells for diagnostic and therapeutic purposes.In the end, the rules in radiobiology should be exploited, in particular, radiosensitivity during G2 andmitotic phases of the cell cycle. Hence, a reasonable approach would be to select a radiolabeled agent with an effective half-life comparable to the doubling time of the tumor cells, which may be estimated from a cell culture derived from a biopsy or less precisely from imaging. Unfortunately, this approach is not practical in using long-lived isotopes due to the dosimetry of radiation burden. An alternative approach is to do serial treatments sronized to the tumor’s native biological clock or with anadjuvant cell cycle arresting agent. Randomized studies are needed to evaluate the effectiveness and practicality of this approach.

DeVita, V.T., Jr. The influence of information on drug resistance on protocol design: The Harry Kaplan Memorial Lecture given at the Fourth International Conference on Malignant Lymphoma,June 6–9, 1990, Lugano, Switzerland. Ann. Oncol. 1991,2, 93-106.

Volkert, W.A.; Goeckeler, W.F.; Ehrhardt, G.J.; Ketring, A.R. Therapeutic radionuclides: Production and decay property considerations. J. Nucl. Med. 1991, 32, 174-185.

Read the full article